Khorana评分与新型维也纳CATS预测评分在HYPERCAN队列癌症患者中的效用
在1286例接受化疗的转移性癌症门诊患者中评估Khorana评分(KRS)与新型维也纳CATS评分对6个月静脉血栓栓塞症(VTE)和死亡的预测价值;6个月内发生120例VTE事件(9.7%),两评分判别力相当,但按预设界值分层后仅新型维也纳CATS评分对VTE分层达统计学显著。
要点
- KRS与新型维也纳CATS评分的c统计量相当。
- 新型维也纳CATS评分以60分为界值时,低危组6.6% vs 高危组12.2%的VTE累积发生率差异有统计学意义(P<0.001)。
- KRS≥2分或新型维也纳CATS评分>60分均为死亡的独立危险因素。
核心结论
- 在本队列中,两种风险评分模型的判别潜力相当;但应用界值后,新型维也纳CATS评分对VTE提供了统计学显著的分层。
- 两种风险评分模型均能有效识别死亡风险增加的患者。
研究设计与样本
- 前瞻性队列研究,纳入新诊断的转移性非小细胞肺癌、结直肠癌、胃癌或乳腺癌门诊患者,共1286例,均在化疗期间。
- 采用以死亡为竞争风险的累积发生率估计和多因素Fine-Gray回归分析。
主要发现
- 6个月内共发生120例VTE事件(9.7%)。
- KRS与新型维也纳CATS评分的c统计量相当。
- 按KRS分层,低、中、高危组VTE累积发生率分别为6.2%、11.4%、11.5%(P=无统计学意义);按单一2分界值分层,低危组 vs 高危组为8.5% vs 11.8%(P=无统计学意义)。
- 按新型维也纳CATS评分预设60分界值,低危组 vs 高危组VTE累积发生率为6.6% vs 12.2%(P<0.001)。
- KRS≥2分或新型维也纳CATS评分>60分是死亡的独立危险因素。
关键数值与推荐
- KRS分层:低危组6.2%、中危组11.4%、高危组11.5%(P=无统计学意义)。
- KRS单一2分界值:低危组8.5% vs 高危组11.8%(P=无统计学意义)。
- 新型维也纳CATS评分60分界值:低危组6.6% vs 高危组12.2%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk assessment models (RAMs) are relevant approaches to identify cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed RAMs, the Khorana (KRS) and the new-Vienna CATS risk scores have been externally validated in ambulatory patients with cancer. OBJECTIVES: To test KRS and new-Vienna CATS scores in 6-month VTE prediction and mortality in a large prospective cohort of metastatic cancer outpatients during chemotherapy. PATIENTS/METHODS: Newly diagnosed patients with metastatic non-small cell lung, colorectal, gastric, or breast cancers were analyzed (n = 1286). The cumulative incidence of objectively confirmed VTE was estimated with death as a competing risk and multivariate Fine and Gray regression. RESULTS: Within 6 months, 120 VTE events (9.7%) occurred. The KRS and the new-Vienna CATS scores showed comparable c-stat. Stratification by KRS provided VTE cumulative incidences of 6.2%, 11.4%, and 11.5% in the low-, intermediate-, and high-risk categories, respectively (p = ns), and of 8.5% vs. 11.8% (p = ns) in the low- vs. high-risk group by the single 2-point cut-off value stratification. Using a pre-defined 60-point cut-off by the new-Vienna CATS score, 6.6% and 12.2% cumulative incidences were obtained in the low- and high-risk groups, respectively (p < 0.001). Furthermore, having a KRS ≥2 = or a new-Vienna CATS score >60 points was also an independent risk factor for mortality. CONCLUSION: In our cohort, the 2 RAMs showed a comparable discriminating potential; however, after the application of cut-off values, the new-Vienna CATS score provided statistically significant stratification for VTE. Both RAMs proved to be effective in identifying patients at increased risk of mortality.
引用
- Verzeroli C, Giaccherini C, Russo L, et al. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort. J Thromb Haemost. 2023. PMID: 37054917. doi:10.1016/j.jtha.2023.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。